Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Jubilant Pharmova share price target

Jubilant Pharmova has several triggers unfolding; maintain ‘BUY’ with TP of ₹1,385 (46% upside): Nuvama



Jubilant Pharmova share price target

Jubilant Pharmova (JPL) posted a strong showing in Q4FY25 with inline revenue, but beating our EBITDA/PAT estimates. EBITDA margins expanded 247bp YoY/213bp QoQ aided by a better product mix.

Jubilant Pharmova is a conviction pick. Buy for target price of ₹1420 (48% upside): ICICI Direct



Jubilant Pharmova share price target

Jubilant Pharmova (JPL) is an integrated, multi-dimensional pharmaceuticals company with global presence. The company was carved out from erstwhile Jubilant Life Sciences to focus on pharma business.

Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!